Axsome Therapeutics Inc
Axsome Therapeutics Inc (AXSM) Implied Volatility Current
AXSM's 30 day implied volatility is 58.14%, with an IV Rank of 85.71%. This is a high IV Rank versus the past year, meaning Axsome Therapeutics Inc options are relatively expensive and currently favor sellers. AXSM's 30 day historical volatility sits at 50.83%, which means implied volatility is running 7.31 points above historical volatility, as of Nov 20, 2026.
Read more
Tracking AXSM implied volatility helps you spot when Axsome Therapeutics Inc options are historically cheap or expensive, and where the best trades are hiding. When AXSM IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor AXSM implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking AXSM IV rank helps you see whether AXSM's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia.
Implied Volatility
IV is highly elevated. Premiums are expensive, strongly favoring sellers.
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →